The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients (Q35619770)

9 August 2017

title

The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients (English)

1 reference

9 August 2017

main subject

metastatic breast cancer

1 reference

1 reference

12

Andreas Schneeweiss

0 references

Florin-Andrei Taran

7

Florin-Andrei Taran

0 references

Sabine Riethdorf

3

Sabine Riethdorf

0 references

Markus Wallwiener

1

Markus Wallwiener

0 references

Martin R. Sprick

Martin Ronald Sprick

5

0 references

Andreas Trumpp

Andreas Trumpp

11

0 references

author name string

Markus Wallwiener

1

1 reference

9 August 2017

Andreas Daniel Hartkopf

2

1 reference

9 August 2017

Juliane Nees

4

1 reference

9 August 2017

Birgitt Schönfisch

6

1 reference

9 August 2017

Jörg Heil

8

1 reference

9 August 2017

Christof Sohn

9

1 reference

9 August 2017

Klaus Pantel

10

1 reference

9 August 2017

language of work or name

English

0 references

publication date

14 May 2015

1 reference

9 August 2017

1 reference

9 August 2017

volume

15

1 reference

9 August 2017

page(s)

403

1 reference

Creative Commons Attribution 4.0 International

9 August 2017

copyright license

start time

14 May 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Trastuzumab Administration in Patients with Metastatic Breast Cancer - Experience of a Large University Breast Center

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

Circulating tumor cells predict survival in early average-to-high risk breast cancer patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

Real-time liquid biopsy in cancer patients: fact or fiction?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

Biomarkers characterization of circulating tumour cells in breast cancer patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

HER2-positive DTCs/CTCs in breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

Clinical implications of the detection of circulating tumor cells in breast cancer patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

HER2-positive circulating tumor cells in breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

HER-2 gene amplification can be acquired as breast cancer progresses

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

erbB-2 (HER-2) and breast cancer progression.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435916

Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer

25 September 2018

1 reference

12 December 2020

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

1 reference

12 December 2020

HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy

1 reference

12 December 2020

High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients

1 reference

12 December 2020

10.1186/S12885-015-1423-6

Identifiers

DOI

1 reference

Dimensions Publication ID

9 August 2017

0 references

1 reference

9 August 2017

1 reference